BD Names Michael Feld as President of Life Sciences Segment
BD (NYSE: BDX) has appointed Michael Feld as the new executive vice president and president of its Life Sciences segment, effective Aug. 20, 2024. Feld, who will join the Executive Leadership Team, succeeds Dave Hickey, who retired last month after a decade with the company. Feld comes from Veralto, a Danaher spin-off, where he was president of Hach. His experience includes senior roles at Danaher, focusing on strategic planning, quality, and cultural progression.
As president of BD Life Sciences, Feld will oversee Biosciences, Diagnostics Solutions, and Specimen Management. The segment aims to deliver innovative advancements from discovery to diagnosis, focusing on smart, connected workflows and diagnostics in new care settings to improve chronic condition management.
BD (NYSE: BDX) ha nominato Michael Feld come nuovo vicepresidente esecutivo e presidente del suo segmento Life Sciences, con effetto 20 agosto 2024. Feld, che entrerà a far parte del Team di Leadership Esecutiva, succede a Dave Hickey, che si è ritirato il mese scorso dopo un decennio in azienda. Feld proviene da Veralto, uno spin-off di Danaher, dove era presidente di Hach. La sua esperienza include ruoli senior in Danaher, con un focus su pianificazione strategica, qualità e progresso culturale.
In qualità di presidente di BD Life Sciences, Feld supervisionerà Biosciences, Diagnostics Solutions e Specimen Management. Il segmento mira a fornire progressi innovativi dalla scoperta alla diagnosi, concentrandosi su flussi di lavoro e diagnosi intelligenti e connesse in nuovi contesti assistenziali per migliorare la gestione delle condizioni croniche.
BD (NYSE: BDX) ha nombrado a Michael Feld como nuevo vicepresidente ejecutivo y presidente de su segmento de Ciencias de la Vida, con efecto a partir del 20 de agosto de 2024. Feld, quien se unirá al Equipo de Liderazgo Ejecutivo, sucederá a Dave Hickey, que se retiró el mes pasado después de una década en la empresa. Feld proviene de Veralto, una escisión de Danaher, donde fue presidente de Hach. Su experiencia incluye roles de alta dirección en Danaher, centrados en la planificación estratégica, la calidad y el avance cultural.
Como presidente de BD Life Sciences, Feld supervisará Biosciences, Diagnostics Solutions y Specimen Management. El segmento tiene como objetivo ofrecer avances innovadores desde el descubrimiento hasta el diagnóstico, enfocándose en flujos de trabajo y diagnósticos inteligentes y conectados en nuevos entornos de atención para mejorar la gestión de condiciones crónicas.
BD (NYSE: BDX)는 Michael Feld를 새로운 총괄 부사장 겸 생명 과학 부문 사장으로 임명하며, 2024년 8월 20일부터 효력이 발생합니다. Feld는 경영진 리더십 팀에 합류하게 되며, 지난달 10년간 회사에 재직한 Dave Hickey의 후임입니다. Feld는 Danaher의 분사 회사인 Veralto에서 Hach의 사장이었습니다. 그의 경험은 Danaher에서 전략적 계획, 품질 및 문화 발전에 초점을 맞춘 고위직을 포함합니다.
BD 생명 과학의 사장으로서 Feld는 생명 과학(Biosciences), 진단 솔루션(Diagnostics Solutions) 및 표본 관리(Specimen Management)를 감독하게 됩니다. 이 부문은 발견에서 진단까지 혁신적인 발전을 제공하고, 만성 질환 관리를 개선하기 위해 새로운 치료 환경에서 스마트하고 연결된 워크플로우와 진단에 중점을 둡니다.
BD (NYSE: BDX) a nommé Michael Feld en tant que nouveau vice-président exécutif et président de son segment des Sciences de la Vie, avec effet à partir du 20 août 2024. Feld, qui rejoindra l'équipe de direction exécutive, succède à Dave Hickey, qui a pris sa retraite le mois dernier après une décennie dans l'entreprise. Feld vient de Veralto, une scission de Danaher, où il était président de Hach. Son expérience comprend des postes de direction chez Danaher, axés sur la planification stratégique, la qualité et le progrès culturel.
En tant que président de BD Life Sciences, Feld supervisera les Biosciences, les Solutions de Diagnostic et la Gestion des Échantillons. Le segment vise à fournir des avancées innovantes, de la découverte au diagnostic, en se concentrant sur des flux de travail intelligents et connectés ainsi que sur des diagnostics dans de nouveaux contextes de soins pour améliorer la gestion des maladies chroniques.
BD (NYSE: BDX) hat Michael Feld zum neuen Executive Vice President und Präsidenten seines Bereichs Life Sciences ernannt, wirksam ab dem 20. August 2024. Feld, der dem Executive Leadership Team beitreten wird, folgt auf Dave Hickey, der letzten Monat nach einem Jahrzehnt im Unternehmen in den Ruhestand gegangen ist. Feld kommt von Veralto, einem Spin-off von Danaher, wo er Präsident von Hach war. Seine Erfahrungen umfassen leitende Positionen bei Danaher mit einem Schwerpunkt auf strategischer Planung, Qualität und kulturellem Fortschritt.
Als Präsident von BD Life Sciences wird Feld die Bereiche Biosciences, Diagnostics Solutions und Specimen Management leiten. Der Bereich hat das Ziel, von der Entdeckung bis zur Diagnose innovative Fortschritte zu erzielen, indem er sich auf intelligente, vernetzte Arbeitsabläufe und diagnostische Verfahren in neuen Pflegekontexten konzentriert, um das Management chronischer Erkrankungen zu verbessern.
- Appointment of experienced executive Michael Feld to lead Life Sciences segment
- Feld's expertise in commercial and operational excellence aligns with BD's strategic goals
- Focus on developing innovative solutions for improved diagnosis and treatment of chronic conditions
- None.
Feld joins BD from Veralto, a spin-off of Danaher, where he was most recently president of Hach, a global leader in water quality products. Prior to that, Feld held several senior roles at Danaher, including senior vice president and general manager of Cepheid Europe, and served as president of several other Danaher businesses including Mammotome, XOS and Dover Motion, all focused on strategic planning, superior quality, associate development and cultural progression.
"Mike's expertise in applying commercial and operational excellence principles to deliver impactful results, coupled with his experience in diagnostic solutions, position him well to lead our Life Sciences segment," said Tom Polen, chairman, CEO and president of BD. "As we build momentum behind our BD Excellence operating system, Mike's continuous improvement mindset will be an asset to BD as our Life Sciences team continues to drive efficiencies and meaningfully expand value for our customers, their patients and the global healthcare ecosystem."
As president of the BD Life Sciences segment, which includes Biosciences, Diagnostics Solutions and Specimen Management, Feld will be responsible for an organization that is delivering innovative advancements from discovery to diagnosis. Under his leadership, BD Life Sciences will continue to focus on developing solutions around smart, connected, end-to-end workflows, specimen collection and diagnostics at new care settings, which will improve the diagnosis and treatment of chronic conditions.
Feld earned his Bachelor of Science degree from Tulane University and his Master of Business Administration from Northwestern University's Kellogg School of Management.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.
Contacts: | |
Media: | Investors: |
Troy Kirkpatrick | Adam Reiffe |
VP, Public Relations | Senior Director, Investor Relations |
858.617.2361 | 201.847.6927 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-names-michael-feld-as-president-of-life-sciences-segment-302219382.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
Who is the new president of BD's Life Sciences segment?
What is Michael Feld's previous experience before joining BD (BDX)?
What areas will Michael Feld oversee as president of BD Life Sciences?
What is the focus of BD's Life Sciences segment under Michael Feld's leadership?
